Xevant, a leader in real-time pharmacy benefits AI and analytics, has officially announced the launch of VerX, which happens to be a powerful new platform geared towards changing the way pharmacy benefits are optimized, managed, and controlled.
According to certain reports, VerX arrives on the scene bearing an ability to reverse engineer prescription claims, and therefore, reveal the lowest achievable net cost for every claim, in real time.
More on that would reveal how the given technology effectively combines predictive modeling, AI simulation, and automated plan correction in a single, scalable platform to help brokers, health plans, PBMs, and self-funded employers identify and achieve immediate savings opportunities. as well as system-level waste across drug mix, channel, formulary, pricing, and rebate alignment.
Leveraging over eight years of industry-leading data infrastructure and analytics performance, and trained on 99% of the PBM market performance, VerX can ingest, at launch, 99% of the PBM market performance.
Talk about the whole value proposition on a slightly deeper level, we begin from the core promise of reverse engineer. Here, VerX actively maps PBM market performance to reach upon real-time, lowest-net-cost pricing.
Next up, we dig into the potential for plan design simulation. This translates to how the given proposition forecasts the cost impact of benefit changes before implementation, including PA edits, step therapy, copay, channel adjustments, and rebate shifts.
Another detail worth a mention is rooted in the facility to track things post-implementation VerX basically compares actual vs. projected savings to ensure accountability across all stakeholders.
Similar to that, there is also a setup in place to facilitate contract performance monitoring. You see, the primary objective in this one is to flag discrepancies in PBM pricing, discount, and rebate.
Hold on, we still have a few bits left to unpack, considering we haven’t yet touched upon the VerX’s focus on optimizing utilization at every single touchpoint. In essence, it highlights high-cost drug mix inefficiencies, and at the same time, pinpoints biosimilar, dose, or channel alternatives.
We also haven’t expanded upon the availability of rebate intelligence, something which treads up a long distance to project accruals and real net cost, thus eliminating guesswork or six-month delays.
Rounding up highlights would be an aspect revolving around disruption analysis. The solution’s approach here involves quantifying the member impact of any savings strategy to protect employee experience.
Among other things, we ought to mention how organizations that bank upon VerX could very well achieve average savings of 15–25%, with some even reaching up to 31% through optimized drug mix, channel management, and formulary realignment. In case that wasn’t enough, they can realize these benefits mid-contract, meaning they don’t have to wait for annual renewals or switching PBMs.
Founded in 2017, Xevant’s rise up the ranks stems from its real-time, AI-powered platforms that make it possible for organizations to reduce waste, optimize contract value, and achieve measurable results across commercial and self-funded markets. The company’s excellence in what it does can also be understood once you consider it is currently relied upon by a host of PBMs, TPAs, brokers, and Fortune 1000 employers nationwide.
“The industry doesn’t need more dashboards. It needs action,” said Brandon Newman, CEO of Xevant. “VerX isn’t just another reporting tool. It’s the backbone of next-generation cost containment and entirely new PBM strategies never conceived before. Most platforms monitor. VerX predicts, simulates, and prescribes actions—backed by proof.”
